005690.KS
Pharmicell Co., Ltd.
KSC · Healthcare · Biotechnology · KR
KRW 9,800.00
−4.20%Year over year
Reported trailing growth
- Revenue
- +51.3%
- EBITDA
- +82.2%
- EBIT
- +109.9%
- EPS
- +124.7%
- Free cash flow
- +30.9%
- Operating cash flow
- +95.5%
Forward estimates
Based on analyst estimates
- Revenue
- -67.0%
- EBITDA
- -52.5%
- EPS
- -64.7%
Three-year CAGR
- Revenue
- +23.8%
- EBITDA
- +60.5%
- EBIT
- +56.1%
- Net income
- +69.6%
- EPS
- +69.6%
- Free cash flow
- +140.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026